1 | J-tube | 1件: Carbidopa Carbidopa | 1件: D00558
D00558
| 1件: DDC DDC 💬 | 9件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 |
2 | J01GB01 | 1件: Tobramycin Tobramycin | 2件: D00063
D00063
,
D02542
| - | - | 1件: 299 299 |
3 | J05A F01 | 1件: Zidovudine Zidovudine | 1件: D00413
D00413
| - | - | 1件: 135 135 |
4 | J1081 | 1件: Interferon alfa-2a Interferon alfa-2a | 1件: D00745
D00745
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 56 56 |
5 | J695 | - | - | - | - | 1件: 96 96 |
6 | J695, BSF 415977 (formerly LU415977), WAY-165772, A-796874.0 | 1件: Interleukin-1 alpha, human recombinant Interleukin-1 alpha, human recombinant | - | - | - | 1件: 96 96 |
7 | JAK 3 | 1件: Captopril Captopril | 1件: D00251
D00251
| 1件: ACE ACE 💬 | 6件: Chagas disease Chagas disease, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Renin secretion, Renin-angiotensin system 💬 | 1件: 46 46 |
8 | JAK 3 Ritlecitinib | 1件: Tofacitinib Tofacitinib | 1件: D09970
D09970
| 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 |
9 | JAK Inhibitor | - | - | - | - | 1件: 50 50 |
10 | JAK1 / JAK2 Inhibitor | - | - | - | - | 1件: 46 46 |
11 | JAK1 / JAK2 Inhibtor | - | - | - | - | 1件: 46 46 |
12 | Jaktinib Dihydrochloride Monohydrate 50mg BID and Mimic tablets of jakitinib hydrochloride 75mg BID and Acetylcysteine Effervescent Tablets | 1件: Acetylcysteine Acetylcysteine | 1件: D00221
D00221
| - | - | 1件: 85 85 |
13 | Jaktinib Dihydrochloride Monohydrate 75mg BID and Mimic tablets of jakitinib hydrochloride 50mg BID and Acetylcysteine Effervescent Tablets | 1件: Acetylcysteine Acetylcysteine | 1件: D00221
D00221
| - | - | 1件: 85 85 |
14 | Jaktinib Hydrochloride Tablets | - | - | - | - | 1件: 271 271 |
15 | Janus Kinase Inhibitor | 1件: Tofacitinib Tofacitinib | 1件: D09970
D09970
| 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 97 97 |
16 | Jardiance | 1件: Empagliflozin Empagliflozin | 1件: D10459
D10459
| - | - | 1件: 65 65 |
17 | JBPOS0101 | 1件: JBPOS0101 JBPOS0101 | - | - | - | 1件: 145 145 |
18 | JBT-101 | - | - | - | - | 4件: 49 49, 50, 51, 299 |
19 | JBT-101 (lenabasum) | - | - | - | - | 1件: 299 299 |
20 | Jejunal extension tube | 1件: Carbidopa Carbidopa | 1件: D00558
D00558
| 1件: DDC DDC 💬 | 9件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 |
21 | Jejunal extension tube (J-tube) | 1件: Carbidopa Carbidopa | 1件: D00558
D00558
| 1件: DDC DDC 💬 | 9件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 |
22 | Jevity 1.0 | - | - | - | - | 1件: 2 2 |
23 | Jevity 1.5 | - | - | - | - | 1件: 2 2 |
24 | JHL1101 | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 |
25 | Jianpixiaozhong particles and Wuse Dietotherapy | - | - | - | - | 1件: 222 222 |
26 | Jin-shui Huan-xian granule | - | - | - | - | 1件: 85 85 |
27 | Jinarc | 1件: Tolvaptan Tolvaptan | 1件: D01213
D01213
| 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 |
28 | JINARC - 15 MG +45 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28X15 MG + 28 X 45 MG) | 1件: Tolvaptan Tolvaptan | 1件: D01213
D01213
| 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 |
29 | JINARC - 15 MG - COMPRESSA - USO ORALE - BLISTER (ALU/PVC) - 28 COMPRESSE | 1件: Metformin Metformin | 2件: D00944
D00944
,
D04966
| 2件: PRKAA1 PRKAA1, PRKAA2 💬 | 20件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬 | 1件: 67 67 |
30 | JINARC - 30 MG + 60 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28 X 30 MG + 28 X 60 MG) | 1件: Tolvaptan Tolvaptan | 1件: D01213
D01213
| 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 |
31 | JINARC - 30 MG +90 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28 X 30 MG + 28 X 90 MG) | 1件: Tolvaptan Tolvaptan | 1件: D01213
D01213
| 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 |
32 | JINARC - 30 MG - COMPRESSA - USO ORALE - BLISTER (ALU/PVC) - 28 COMPRESSE | 1件: Metformin Metformin | 2件: D00944
D00944
,
D04966
| 2件: PRKAA1 PRKAA1, PRKAA2 💬 | 20件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬 | 1件: 67 67 |
33 | Jinarc - Tolvaptan tablets | 1件: Tolvaptan Tolvaptan | 1件: D01213
D01213
| 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 |
34 | Jinarc 15 mg tablets, Jinarc 45 mg tablets | 1件: Tolvaptan Tolvaptan | 1件: D01213
D01213
| 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 |
35 | Jinarc 30 mg Tablet | 1件: Tolvaptan Tolvaptan | 1件: D01213
D01213
| 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 |
36 | Jinarc 30 mg tablets, 90 mg tablets | 1件: Tolvaptan Tolvaptan | 1件: D01213
D01213
| 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 |
37 | Jinarc 30 mg tablets, Jinarc 60 mg tablets | 1件: Tolvaptan Tolvaptan | 1件: D01213
D01213
| 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 |
38 | Jinarc® 15mg Tablet | 1件: Tolvaptan Tolvaptan | 1件: D01213
D01213
| 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 |
39 | Jinarc® 30 Tablet | 1件: Tolvaptan Tolvaptan | 1件: D01213
D01213
| 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 |
40 | Jing Si Herbal Tea LIQUID PACKETS | 1件: Tea leaf Tea leaf | - | - | - | 2件: 46 46, 271 |
41 | Jintropin AQ | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 78 78 |
42 | JKB-122 | - | - | - | - | 1件: 95 95 |
43 | JKB-122 in capsule or tablet form | - | - | - | - | 1件: 95 95 |
44 | JM | 1件: Josamycin Josamycin | 1件: D01235
D01235
| - | - | 2件: 6 6, 13 |
45 | JM-010 | 1件: Josamycin Josamycin | 1件: D01235
D01235
| - | - | 1件: 6 6 |
46 | JM-010 group A | 1件: Josamycin Josamycin | 1件: D01235
D01235
| - | - | 1件: 6 6 |
47 | JM-010 group B | 1件: Josamycin Josamycin | 1件: D01235
D01235
| - | - | 1件: 6 6 |
48 | JM-4 | 1件: Josamycin Josamycin | 1件: D01235
D01235
| - | - | 1件: 13 13 |
49 | JNJ 38518168 | - | - | - | - | 1件: 46 46 |
50 | JnJ 54767414 | 1件: Hyaluronidase (human recombinant) Hyaluronidase (human recombinant) | - | - | - | 1件: 28 28 |
51 | JNJ-16240159-AAC | - | - | - | - | 1件: 46 46 |
52 | JNJ-31001074 | 1件: Bavisant Bavisant | 1件: D09870
D09870
| 1件: HRH3 HRH3 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 6 6 |
53 | JNJ-38518168 | - | - | - | - | 1件: 46 46 |
54 | JNJ-38518168 (10 mg) | 1件: Methotrexate Methotrexate | 2件: D00142
D00142
,
D02115
| 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 |
55 | JNJ-38518168 (3 mg) | 1件: Methotrexate Methotrexate | 2件: D00142
D00142
,
D02115
| 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 |
56 | JNJ-38518168 (30 mg) | 1件: Methotrexate Methotrexate | 2件: D00142
D00142
,
D02115
| 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 |
57 | JNJ-38518168 / MTX | 1件: Methotrexate Methotrexate | 2件: D00142
D00142
,
D02115
| 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 |
58 | JNJ-38518168 50-mg Over Encapsulated Tablet | - | - | - | - | 1件: 46 46 |
59 | JNJ-38518168-AEK - Over Encapsulated Tablet - 50 mg | - | - | - | - | 1件: 46 46 |
60 | JNJ-38518168-ZBQ | - | - | - | - | 1件: 46 46 |
61 | JNJ-38518168-ZBQ - film-coated tablet - 10 mg | - | - | - | - | 1件: 46 46 |
62 | JNJ-38518168-ZBQ - film-coated tablet - 10mg | - | - | - | - | 1件: 46 46 |
63 | JNJ-38518168-ZBQ - film-coated tablet - 3 mg | - | - | - | - | 1件: 46 46 |
64 | JNJ-38518168-ZBQ - film-coated tablet - 30 mg | - | - | - | - | 1件: 46 46 |
65 | JNJ-38518168-ZBQ - film-coated tablet - 30mg | - | - | - | - | 1件: 46 46 |
66 | JNJ-38518168-ZBQ - film-coated tablet - 3mg | - | - | - | - | 1件: 46 46 |
67 | JNJ-39039039 | 1件: Acetylsalicylic acid Acetylsalicylic acid | 1件: D00109
D00109
| 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 210 210 |
68 | JNJ-39758979 | - | - | - | - | 1件: 46 46 |
69 | JNJ-39758979 (10 mg) | - | - | - | - | 1件: 46 46 |
70 | JNJ-39758979 (100 mg) | - | - | - | - | 1件: 46 46 |
71 | JNJ-39758979 (30 mg) | - | - | - | - | 1件: 46 46 |
72 | JNJ-39758979 (300 mg) | - | - | - | - | 1件: 46 46 |
73 | JNJ-39758979 / MTX | 1件: Methotrexate Methotrexate | 2件: D00142
D00142
,
D02115
| 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 |
74 | JNJ-39758979-AAC - enteric coated tablet - 10 mg | - | - | - | - | 1件: 46 46 |
75 | JNJ-39758979-AAC - enteric coated tablet - 100 mg | - | - | - | - | 1件: 46 46 |
76 | JNJ-39758979-AAC - enteric coated tablet - 30 mg | - | - | - | - | 1件: 46 46 |
77 | JNJ-40346527 | 1件: JNJ-40346527 JNJ-40346527 | - | - | - | 2件: 46 46, 96 |
78 | JNJ-40346527-AAC | 1件: JNJ-40346527 JNJ-40346527 | - | - | - | 1件: 96 96 |
79 | JNJ-40346527-AAC - capsule - 50 mg | 1件: JNJ-40346527 JNJ-40346527 | - | - | - | 1件: 46 46 |
80 | JNJ-42160443 | - | - | - | - | 1件: 226 226 |
81 | JNJ-54767414 | 1件: Hyaluronidase (human recombinant) Hyaluronidase (human recombinant) | - | - | - | 2件: 28 28, 49 |
82 | JNJ-54781532 150 mg once daily | - | - | - | - | 1件: 97 97 |
83 | JNJ-54781532 25 mg once daily | - | - | - | - | 1件: 97 97 |
84 | JNJ-54781532 75 mg once daily | - | - | - | - | 1件: 97 97 |
85 | JNJ-54781532 75 mg twice daily | - | - | - | - | 1件: 97 97 |
86 | JNJ-54781532-AAD-10 mg | - | - | - | - | 1件: 97 97 |
87 | JNJ-54781532-AAD-30 mg | - | - | - | - | 1件: 97 97 |
88 | JNJ-54781532-AAD-5 mg | - | - | - | - | 1件: 97 97 |
89 | JNJ-55920839 | - | - | - | - | 1件: 49 49 |
90 | JNJ-56022473 | - | - | - | - | 1件: 49 49 |
91 | JNJ-64304500 | 1件: Adalimumab Adalimumab | 1件: D02597
D02597
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 |
92 | JNJ-64304500-AAA | 1件: Ustekinumab Ustekinumab | 1件: D09214
D09214
| 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 |
93 | JNJ-66525433 | - | - | - | - | 1件: 97 97 |
94 | JNJ-67484703 | - | - | - | - | 1件: 46 46 |
95 | JNJ-67864238 | - | - | - | - | 1件: 96 96 |
96 | JNJ-67896049 | - | - | - | - | 1件: 86 86 |
97 | JNJ-67896049 (ACT-293987) | 1件: Selexipag Selexipag | 1件: D09994
D09994
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
98 | JNJ-67896062 / ACT-064992 | 1件: Macitentan Macitentan | 1件: D10135
D10135
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 88 |
99 | JNJ-72537634 | - | - | - | - | 1件: 97 97 |
100 | JNJ-78934804 | 1件: Golimumab Golimumab | 1件: D04358
D04358
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 96 96, 97 |
101 | JNJ-80202135 | 1件: Nipocalimab Nipocalimab | 1件: D11666
D11666
| - | - | 4件: 11 11, 46, 49, 53 |
102 | JNJ31-31001074 | 1件: Bavisant Bavisant | 1件: D09870
D09870
| 1件: HRH3 HRH3 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 6 6 |
103 | Jojoba oil | 1件: Broccoli Broccoli | - | - | - | 1件: 36 36 |
104 | Jojoba oil with broccoli sprout extract | 1件: Broccoli Broccoli | - | - | - | 1件: 36 36 |
105 | Jorveza | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
106 | Jorveza 0.5 mg compresse orodispersibili | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
107 | Jorveza 0.5 mg orodispersible tablets | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
108 | Jorveza 1 mg compresse orodispersibili | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
109 | Jorveza 1 mg orodispersible tablets | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
110 | JP 1730 | 1件: Apomorphine Apomorphine | 2件: D02004
D02004
,
D07460
| 2件: DRD1 DRD1, DRD2 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
111 | JP-1730/F01 | 1件: Fipamezole Fipamezole | - | - | - | 2件: 6 6, 17 |
112 | JP-1730/F02 | 1件: Fipamezole Fipamezole | - | - | - | 2件: 6 6, 17 |
113 | JP-1730/F03 | 1件: Fipamezole Fipamezole | - | - | - | 2件: 6 6, 17 |
114 | JR-141 | - | - | - | - | 1件: 19 19 |
115 | JR-141 or Idursulfase | 1件: Idursulfase Idursulfase | 1件: D04499
D04499
| 1件: IDS IDS 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 |
116 | JR-171 | - | - | - | - | 1件: 19 19 |
117 | JS002 | - | - | - | - | 1件: 79 79 |
118 | JS005 | - | - | - | - | 1件: 271 271 |
119 | JSP191 | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 285 285 |
120 | JTE-051 | - | - | - | - | 1件: 46 46 |
121 | JTT-251 | - | - | - | - | 1件: 86 86 |
122 | Juanbi pill | 1件: Methotrexate Methotrexate | 2件: D00142
D00142
,
D02115
| 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 |
123 | Juvit D3 | - | - | - | - | 1件: 6 6 |
124 | Jyseleca | 1件: Filgotinib Filgotinib | 1件: D10871
D10871
| 1件: JAK1 JAK1 💬 | 27件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 |
125 | Jyseleca 100 mg film-coated tablets | 1件: Filgotinib Filgotinib | 1件: D10871
D10871
| 1件: JAK1 JAK1 💬 | 27件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 |
126 | Jyseleca 200 mg film-coated tablets | 1件: Filgotinib Filgotinib | 1件: D10871
D10871
| 1件: JAK1 JAK1 💬 | 27件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 |
127 | JZP-110 | - | - | - | - | 1件: 6 6 |